Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Millendo Therapeutics Inc (MLND) USD0.001

Sell:$1.87 Buy:$1.88 Change: $0.05 (2.73%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.05 (2.73%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.05 (2.73%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Millendo Therapeutics, Inc., formerly OvaScience, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing novel treatments for orphan endocrine diseases. The Company is focused on advancing two product candidates to treat three indications. Its advanced product candidate, livoletide (AZP-531), is a potential treatment for Prader-Willi syndrome (PWS), which is a rare and complex genetic endocrine disease characterized by hyperphagia, or insatiable hunger. It is also developing nevanimibe (ATR-101) with a primary focus on treating patients with classic congenital adrenal hyperplasia (CAH), which is a rare, monogenic adrenal disease that requires lifelong treatment with exogenous cortisol.

Contact details

110 Miller Ave Ste 100
United States
+1 (734) 8459000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$36.29 million
Shares in issue:
19.00 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Carol Gallagher
    Independent Chairman of the Board
  • Julia Owens
    President, Chief Executive Officer, Director
  • Louis Arcudi
    Chief Financial Officer
  • Tamara Joseph
    General Counsel, Corporate Secretary
  • Christophe Arbet-Engels
    Chief Medical Officer
  • Thomas Hoover
    Chief Commercial Officer
  • Ryan Zeidan
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.